Reader sentiment, not investment advice. One vote per visitor; click again to change it.
MDLN is priced at $34.45 right now, down 0.72% on the session. That puts its market value at $30.22B, 439th largest among the 800 stocks we cover.
Over a full year the shares have ranged across $31.49 to $50.88, which puts the current price roughly 15% of the way up that band.
For the quarter ended Jun 2026 it reported $7.69B in revenue, up 11.6% from a year earlier, with $139.00M of net profit (a 2.3% margin).
The stock changes hands at 65.4 times trailing earnings, 79% above its five-year average of 36.5. The median for its industry group is 30.7.
20 analysts follow the stock and the average call is "buy". The mean target, $44.88, sits 30.3% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 3 factors below, ranked against the 800 U.S. stocks BeStock covers.
Cheaper than usual on its own 5-year P/E history scores higher.
Trading closer to its 52-week high than most peers scores higher.
20 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
MDLN is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2020-07-06, the strategy has returned 1524.8% (321.7% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $44.88, 30.3% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $43.00, so shares trade 19.9% below that estimate. On earnings multiple, it sits in the 92nd percentile of its own five-year valuation range (pricier than usual).
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Quote as of Oct 1, 2026 11:50 am ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 800 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Set against the peer table: at 65.4x earnings, MDLN looks about mid-pack against the market, and trades 113% above the 30.7x median among Medical Instruments & Supplies names. The two comparisons do not always agree.
$34.45 is the latest print for MDLN, a move of -0.72% against yesterday's close of $34.70. Today's low and high so far: $34.14 and $35.29.
Equity value comes to $30.22B at the current price. By that measure it is number 439 of the 800 names in our coverage.
Buyers pay 65.4 times the last twelve months of profit (EPS $1.43). Averaged over five years the multiple has been 36.5, and today's level ranks in the 92nd percentile of its own history.
The year's floor is $31.49 and the ceiling $50.88. Shares are 32.3% away from that ceiling.
Our data shows no dividend paid by Medline over the trailing twelve months.
Of 20 analysts, 90% say buy, 10% hold and 0% sell. Price targets average $44.88, with the most cautious at $34.00 and the most optimistic at $55.00.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on MDLN.